RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.65 / 10
Netural
Fund flow is strong (7.83/10) with positive inflows across all investor sizes. Sentiment is neutral. Analysts are split 50% Strong Buy, 50% Buy, but recent price fell 15.34% and market outlook is pessimistic, highlighting risk.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-02
InstitutionLUCID CAPITAL MARKETS
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of RLMD?
- RLMD holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.65/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
